Reckitt Benckiser makes out big time on the misery of U.S. flu sufferers

The fact that this flu season's vaccines were not very effective was bad news for people hoping to avoid the condition but great news for the U.K.'s Reckitt Benckiser Group, which racked up an impressive first quarter on sales of over-the-counter flu meds like Mucinex. Its Q1 sales were up 13%, its best quarter in a couple of years, Bloomberg reports. The rate of flu related hospitalization in the U.S. was twice what it was the year before, an example of how poorly the vaccines worked this year, as the flu mutated into different strains from those the vaccines targeted. RB this week had to recall 1.5 million bottles of Mucinex in the U.S. after discovering some bottles had faulty labels. Story | More | More

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.